Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer

Alex R. Menter, Nikki M. Carroll, Lori C. Sakoda, Thomas Delate, Mark C. Hornbrook, Rakesh K. Jain, Lawrence H. Kushi, Virginia P. Quinn, Debra P. Ritzwoller

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). Patients and Methods: In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS-NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions. Survival differences between those who did and did not receive ASIs concomitant with chemotherapy (CP or CPB) were assessed using propensity score-matched proportional hazard models. OS was measured from the initiation of chemotherapy until death, disenrollment, or December 31, 2012. Results: Of the 1465 CP and 348 CPB patients included, 273 (19%) and 78 (22%), respectively, received concomitant ASI. For CP patients with and without concomitant ASI exposure, median OS was 12.0 and 8.4 months, respectively (crude hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.63-0.84). For CPB patients, the comparable median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95% CI, 0.57-1.02). Using propensity score-matched cohorts, the HR for concomitant ASI use was 0.73 (95% CI, 0.61-0.88) for CP patients and 0.79 (95% CI, 0.51-1.21) for CPB patients. Conclusion: Concomitant ASI receipt during CP or CPB therapy for NS-NSCLC was associated with improved survival, although the association was only statistically significant in the CP group.

Original languageEnglish (US)
JournalClinical Lung Cancer
DOIs
StateAccepted/In press - Apr 20 2016

Fingerprint

Angiotensins
Carboplatin
Non-Small Cell Lung Carcinoma
Paclitaxel
Drug Therapy
Survival
Confidence Intervals
Propensity Score
Retrospective Studies
Proportional Hazards Models
Registries
Neoplasms
Cohort Studies
Perfusion

Keywords

  • Angiotensin
  • Bevacizumab
  • Chemotherapy
  • Microenvironment
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Menter, A. R., Carroll, N. M., Sakoda, L. C., Delate, T., Hornbrook, M. C., Jain, R. K., ... Ritzwoller, D. P. (Accepted/In press). Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2016.07.008

Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. / Menter, Alex R.; Carroll, Nikki M.; Sakoda, Lori C.; Delate, Thomas; Hornbrook, Mark C.; Jain, Rakesh K.; Kushi, Lawrence H.; Quinn, Virginia P.; Ritzwoller, Debra P.

In: Clinical Lung Cancer, 20.04.2016.

Research output: Contribution to journalArticle

Menter, Alex R. ; Carroll, Nikki M. ; Sakoda, Lori C. ; Delate, Thomas ; Hornbrook, Mark C. ; Jain, Rakesh K. ; Kushi, Lawrence H. ; Quinn, Virginia P. ; Ritzwoller, Debra P. / Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. In: Clinical Lung Cancer. 2016.
@article{a6904e41966443e6985e108e20978640,
title = "Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer",
abstract = "Introduction: Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). Patients and Methods: In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS-NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions. Survival differences between those who did and did not receive ASIs concomitant with chemotherapy (CP or CPB) were assessed using propensity score-matched proportional hazard models. OS was measured from the initiation of chemotherapy until death, disenrollment, or December 31, 2012. Results: Of the 1465 CP and 348 CPB patients included, 273 (19{\%}) and 78 (22{\%}), respectively, received concomitant ASI. For CP patients with and without concomitant ASI exposure, median OS was 12.0 and 8.4 months, respectively (crude hazard ratio [HR], 0.72; 95{\%} confidence interval [CI], 0.63-0.84). For CPB patients, the comparable median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95{\%} CI, 0.57-1.02). Using propensity score-matched cohorts, the HR for concomitant ASI use was 0.73 (95{\%} CI, 0.61-0.88) for CP patients and 0.79 (95{\%} CI, 0.51-1.21) for CPB patients. Conclusion: Concomitant ASI receipt during CP or CPB therapy for NS-NSCLC was associated with improved survival, although the association was only statistically significant in the CP group.",
keywords = "Angiotensin, Bevacizumab, Chemotherapy, Microenvironment, Non-small-cell lung cancer",
author = "Menter, {Alex R.} and Carroll, {Nikki M.} and Sakoda, {Lori C.} and Thomas Delate and Hornbrook, {Mark C.} and Jain, {Rakesh K.} and Kushi, {Lawrence H.} and Quinn, {Virginia P.} and Ritzwoller, {Debra P.}",
year = "2016",
month = "4",
day = "20",
doi = "10.1016/j.cllc.2016.07.008",
language = "English (US)",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer

AU - Menter, Alex R.

AU - Carroll, Nikki M.

AU - Sakoda, Lori C.

AU - Delate, Thomas

AU - Hornbrook, Mark C.

AU - Jain, Rakesh K.

AU - Kushi, Lawrence H.

AU - Quinn, Virginia P.

AU - Ritzwoller, Debra P.

PY - 2016/4/20

Y1 - 2016/4/20

N2 - Introduction: Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). Patients and Methods: In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS-NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions. Survival differences between those who did and did not receive ASIs concomitant with chemotherapy (CP or CPB) were assessed using propensity score-matched proportional hazard models. OS was measured from the initiation of chemotherapy until death, disenrollment, or December 31, 2012. Results: Of the 1465 CP and 348 CPB patients included, 273 (19%) and 78 (22%), respectively, received concomitant ASI. For CP patients with and without concomitant ASI exposure, median OS was 12.0 and 8.4 months, respectively (crude hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.63-0.84). For CPB patients, the comparable median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95% CI, 0.57-1.02). Using propensity score-matched cohorts, the HR for concomitant ASI use was 0.73 (95% CI, 0.61-0.88) for CP patients and 0.79 (95% CI, 0.51-1.21) for CPB patients. Conclusion: Concomitant ASI receipt during CP or CPB therapy for NS-NSCLC was associated with improved survival, although the association was only statistically significant in the CP group.

AB - Introduction: Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). Patients and Methods: In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS-NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions. Survival differences between those who did and did not receive ASIs concomitant with chemotherapy (CP or CPB) were assessed using propensity score-matched proportional hazard models. OS was measured from the initiation of chemotherapy until death, disenrollment, or December 31, 2012. Results: Of the 1465 CP and 348 CPB patients included, 273 (19%) and 78 (22%), respectively, received concomitant ASI. For CP patients with and without concomitant ASI exposure, median OS was 12.0 and 8.4 months, respectively (crude hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.63-0.84). For CPB patients, the comparable median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95% CI, 0.57-1.02). Using propensity score-matched cohorts, the HR for concomitant ASI use was 0.73 (95% CI, 0.61-0.88) for CP patients and 0.79 (95% CI, 0.51-1.21) for CPB patients. Conclusion: Concomitant ASI receipt during CP or CPB therapy for NS-NSCLC was associated with improved survival, although the association was only statistically significant in the CP group.

KW - Angiotensin

KW - Bevacizumab

KW - Chemotherapy

KW - Microenvironment

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84994891094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994891094&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2016.07.008

DO - 10.1016/j.cllc.2016.07.008

M3 - Article

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -